Within public breast cancer cohorts that underwent NAC, SYTL4 was also highly expressed in non-pCR patients (GSE22513) and upregulated in post-NAC samples (GSE32603) (Figure S3C-D). This evidence concerns the gene SYTL4 and breast cancer.